▁Introduction 10.375
: 6.5234375
<0x0A> 3.994140625
In 4.58203125
▁the 1.7373046875
▁rel 10.0546875
ent 1.5283203125
less 0.09307861328125
▁fight 4.46484375
▁against 0.93310546875
▁cancer 3.259765625
, 0.2308349609375
▁British 8.5390625
▁Bi 8.6015625
ote 0.681640625
ch 0.669921875
▁Pl 6.609375
c 0.0736083984375
' 2.853515625
s 0.0047149658203125
▁experimental 6.6875
▁drug 1.59765625
, 1.5810546875
▁Mar 7.609375
im 5.296875
ast 3.302734375
at 0.05975341796875
, 0.40576171875
▁has 1.0888671875
▁emer 4.96484375
ged 0.0012636184692382812
▁as 0.223876953125
▁a 0.6455078125
▁prom 2.642578125
ising 0.0005307197570800781
▁candidate 2.3984375
▁for 1.404296875
▁potentially 6.578125
▁revolution 3.953125
izing 0.75146484375
▁cancer 2.478515625
▁treatment 0.5302734375
. 0.347412109375
▁Early 8.1328125
▁results 1.935546875
▁and 6.578125
▁encourag 3.45703125
ing 0.01184844970703125
▁data 2.537109375
▁have 2.123046875
▁raised 4.47265625
▁hopes 0.59228515625
▁for 1.625
▁an 3.5078125
▁effective 1.044921875
▁ther 3.01953125
apy 0.003787994384765625
, 2.6875
▁but 1.5654296875
▁the 1.5263671875
▁drug 1.36328125
▁still 3.48046875
▁faces 1.6728515625
▁significant 2.5625
▁obst 2.630859375
acles 0.0005140304565429688
▁before 1.919921875
▁it 0.45556640625
▁can 0.65869140625
▁achieve 4.94140625
▁block 9.1015625
b 0.0093231201171875
uster 0.003692626953125
▁status 0.34228515625
. 0.1990966796875
▁As 4.56640625
▁the 1.5126953125
▁bi 3.900390625
ote 0.055328369140625
ch 0.1605224609375
▁industry 0.978515625
▁eager 8.21875
ly 0.0011663436889648438
▁a 0.2958984375
wa 0.0005917549133300781
its 3.635883331298828e-05
▁further 3.544921875
▁adv 4.6796875
anc 1.0439453125
ements 0.0005178451538085938
, 0.87841796875
▁the 1.916015625
▁road 6.59375
▁ahead 0.81201171875
▁for 2.10546875
▁Mar 0.384765625
im 0.0020275115966796875
ast 0.0035552978515625
at 0.0005774497985839844
▁remains 2.458984375
▁uncertain 1.58984375
▁due 6.5625
▁to 0.04058837890625
▁regul 4.12109375
atory 0.0140228271484375
▁challeng 2.740234375
es 3.6597251892089844e-05
, 0.98046875
▁inten 6.42578125
se 5.6862831115722656e-05
▁competition 0.1954345703125
, 0.5029296875
▁and 0.1817626953125
▁potential 4.85546875
▁financial 4.16796875
▁hur 3.5625
d 0.0001462697982788086
les 0.0002911090850830078
. 0.14990234375
<0x0A> 0.5966796875
Reg 5.81640625
ul 0.142822265625
atory 0.0147247314453125
▁Ch 1.4736328125
alleng 0.00936126708984375
es 7.390975952148438e-05
: 1.73828125
<0x0A> 0.62255859375
Des 4.29296875
p 0.01442718505859375
ite 3.910064697265625e-05
▁demonstr 6.46875
ating 0.0382080078125
▁promise 3.427734375
, 1.2177734375
▁Mar 0.919921875
im 0.00109100341796875
ast 0.0034732818603515625
at 0.0007867813110351562
▁must 3.564453125
▁navigate 2.44140625
▁a 0.9462890625
▁complex 1.0107421875
▁and 2.865234375
▁rig 4.0625
orous 0.11138916015625
▁regul 0.29248046875
atory 8.58306884765625e-05
▁process 1.3076171875
▁before 1.4658203125
▁reaching 3.572265625
▁the 0.47607421875
▁market 0.51220703125
. 0.307373046875
▁The 1.2529296875
▁drug 1.013671875
' 1.2841796875
s 0.00011146068572998047
▁effic 5.05078125
acy 2.956390380859375e-05
▁and 0.68212890625
▁safety 0.057342529296875
▁profile 3.41015625
▁will 2.994140625
▁be 0.75732421875
▁crit 5.4375
ically 0.0035686492919921875
▁review 3.15234375
ed 1.9073486328125e-05
▁by 0.21142578125
▁regul 1.7099609375
atory 0.273681640625
▁authorities 0.76611328125
▁such 3.35546875
▁as 0.002288818359375
▁the 0.03509521484375
▁U 1.01171875
. 0.00021147727966308594
S 0.01971435546875
. 0.0191650390625
▁Food 0.04046630859375
▁and 0.09014892578125
▁D 0.0008320808410644531
rug 3.814697265625e-05
▁Administration 0.005901336669921875
▁( 0.22265625
F 0.00925445556640625
DA 0.0004706382751464844
) 0.4482421875
▁and 0.07220458984375
▁the 0.431396484375
▁European 0.172119140625
▁Medic 0.054595947265625
ines 0.0012989044189453125
▁Agency 0.0162353515625
▁( 0.0908203125
EMA 0.0041961669921875
). 0.70947265625
▁Given 5.09765625
▁the 0.442626953125
▁string 6.09765625
ent 0.006023406982421875
▁requirements 1.193359375
▁and 1.5419921875
▁extensive 3.189453125
▁testing 1.7646484375
▁phases 7.13671875
▁involved 3.171875
, 0.475341796875
▁British 6.63671875
▁Bi 0.013763427734375
ote 9.381771087646484e-05
ch 0.005039215087890625
▁Pl 1.3935546875
c 0.0005669593811035156
▁must 1.583984375
▁address 5.0546875
▁any 3.4765625
▁potential 1.451171875
▁concerns 2.302734375
▁or 2.6328125
▁side 5.4609375
▁effects 0.0540771484375
▁to 2.31640625
▁ensure 0.9375
▁Mar 3.177734375
im 0.0005369186401367188
ast 0.002834320068359375
at 0.0008111000061035156
' 1.4580078125
s 0.0003173351287841797
▁successful 4.68359375
▁journey 8.0546875
▁through 2.3984375
▁regul 2.490234375
atory 0.0033550262451171875
▁appro 0.54296875
val 5.5670738220214844e-05
. 0.373291015625
<0x0A> 0.28515625
Int 1.814453125
ense 0.11737060546875
▁Compet 0.11968994140625
ition 0.0009741783142089844
▁and 5.0078125
▁Market 5.125
▁Land 5.390625
s 0.0083770751953125
cape 3.933906555175781e-06
: 0.056884765625
<0x0A> 0.00579071044921875
Mar 1.578125
im 0.0013217926025390625
ast 0.0020236968994140625
at 0.000469207763671875
▁enters 7.62109375
▁a 0.49169921875
▁fier 3.8046875
c 0.26708984375
ely 2.86102294921875e-06
▁compet 0.025634765625
itive 9.465217590332031e-05
▁market 0.395751953125
, 1.2587890625
▁challeng 5.76953125
ing 1.2236328125
▁established 2.220703125
▁players 0.90380859375
▁who 5.390625
▁have 1.08984375
▁already 3.625
▁made 4.0234375
▁significant 0.51171875
▁str 1.822265625
ides 1.0728836059570312e-06
▁in 0.1947021484375
▁cancer 1.2001953125
▁treatment 0.444580078125
. 0.1358642578125
▁R 5.73046875
ival 0.10113525390625
▁ph 4.5
arma 0.000797271728515625
ce 0.01021575927734375
ut 1.7881393432617188e-06
ical 4.208087921142578e-05
▁companies 0.255859375
▁have 2.720703125
▁inv 2.5546875
ested 5.710124969482422e-05
▁heavily 0.41455078125
▁in 0.129150390625
▁developing 1.619140625
▁cutting 4.50390625
- 0.00615692138671875
edge 0.0008721351623535156
▁ther 1.0380859375
ap 0.0009984970092773438
ies 5.125999450683594e-06
, 0.94677734375
▁some 5.3125
▁of 0.0745849609375
▁which 0.0020694732666015625
▁have 1.2431640625
▁gained 4.12109375
▁regul 2.21484375
atory 0.0003323554992675781
▁appro 0.0249786376953125
val 7.510185241699219e-06
▁and 0.6796875
▁achieved 3.021484375
▁impress 3.595703125
ive 0.00018095970153808594
▁clin 4.15234375
ical 0.00040841102600097656
▁out 2.619140625
comes 6.973743438720703e-05
. 0.0765380859375
▁British 2.142578125
▁Bi 0.0017004013061523438
ote 4.4226646423339844e-05
ch 0.00199127197265625
▁Pl 0.066650390625
c 7.891654968261719e-05
▁must 0.650390625
▁find 4.65625
▁its 5.359375
▁place 1.771484375
▁within 2.435546875
▁this 0.8154296875
▁crow 1.744140625
ded 6.783008575439453e-05
▁landscape 1.255859375
▁by 2.361328125
▁demonstr 2.6796875
ating 3.063678741455078e-05
▁a 2.751953125
▁unique 1.09765625
▁value 1.18359375
▁proposition 0.0130767822265625
▁and 0.619140625
▁differenti 1.7431640625
ating 1.005859375
▁Mar 3.8359375
im 0.0002613067626953125
ast 0.0015201568603515625
at 0.00025582313537597656
▁from 0.300537109375
▁existing 1.7412109375
▁treatment 4.01171875
▁options 0.0255889892578125
. 0.027862548828125
<0x0A> 0.1644287109375
Fin 0.91064453125
an 0.043975830078125
cial 0.0004906654357910156
▁Con 5.30859375
stra 0.0035991668701171875
ints 0.004150390625
▁and 2.576171875
▁Market 3.9140625
▁Access 2.771484375
: 0.2215576171875
<0x0A> 0.0025787353515625
Develop 6.47265625
ing 0.15966796875
▁and 1.59765625
▁launch 2.69140625
ing 1.537799835205078e-05
▁a 0.21142578125
▁ground 5.01953125
bre 0.15380859375
aking 0.00020384788513183594
▁cancer 1.1513671875
▁drug 2.01953125
▁is 1.2412109375
▁an 2.646484375
▁expensive 0.39599609375
▁ende 1.6171875
avor 3.254413604736328e-05
, 0.497802734375
▁requiring 3.03515625
▁substantial 2.1484375
▁financial 3.25
▁resources 0.6591796875
. 1.4794921875
▁British 0.9453125
▁Bi 0.0006833076477050781
ote 4.9233436584472656e-05
ch 0.001346588134765625
▁Pl 0.0194854736328125
c 7.390975952148438e-05
▁may 4.046875
▁face 0.853515625
▁hur 4.65234375
d 1.9073486328125e-05
les 0.0003986358642578125
▁in 0.66455078125
▁se 1.2109375
cur 7.343292236328125e-05
ing 6.079673767089844e-06
▁the 1.6025390625
▁fund 1.955078125
ing 0.00054931640625
▁necessary 0.884765625
▁for 2.197265625
▁the 1.880859375
▁drug 2.306640625
' 0.024688720703125
s 5.364418029785156e-05
▁clin 3.390625
ical 0.00027823448181152344
▁tri 0.4677734375
als 1.1920928955078125e-06
, 1.8095703125
▁manufact 1.9091796875
uring 0.0080413818359375
, 1.15234375
▁and 0.1016845703125
▁market 0.796875
ing 0.1055908203125
▁activities 4.75
. 0.075439453125
▁Additionally 2.142578125
, 7.152557373046875e-05
▁questions 9.8515625
▁regarding 2.560546875
▁re 3.96875
imb 0.00827789306640625
urs 2.8252601623535156e-05
ement 0.005828857421875
▁and 0.677734375
▁market 4.64453125
▁access 0.031768798828125
▁also 5.51171875
▁pose 2.1640625
▁challeng 1.0625
es 0.004169464111328125
. 2.2578125
▁Dem 8.25
on 0.1397705078125
str 0.0186004638671875
ating 0.045074462890625
▁the 1.5546875
▁cost 4.12890625
- 0.11480712890625
effect 0.0784912109375
iveness 0.004665374755859375
▁and 1.4306640625
▁real 6.2578125
- 0.1817626953125
world 0.016876220703125
▁benefits 1.6865234375
▁of 0.0301971435546875
▁Mar 0.09185791015625
im 7.18832015991211e-05
ast 0.0015087127685546875
at 0.00011777877807617188
▁will 1.8671875
▁be 0.205078125
▁critical 0.99365234375
▁to 0.7314453125
▁se 2.60546875
cur 0.0010347366333007812
ing 4.410743713378906e-06
▁ins 4.56640625
urance 0.0589599609375
▁coverage 0.052886962890625
▁and 0.17919921875
▁a 4.5078125
▁fair 3.59765625
▁pr 4.6015625
icing 0.0016717910766601562
▁structure 0.796875
, 3.025390625
▁a 4.7421875
▁factor 4.4140625
▁that 0.1474609375
▁can 2.671875
▁greatly 2.654296875
▁influence 1.3330078125
▁its 2.076171875
▁block 11.171875
b 0.0002295970916748047
uster 0.0017833709716796875
▁potential 0.1795654296875
. 0.049957275390625
<0x0A> 0.0256195068359375
C 4.8984375
lin 1.5087890625
ical 0.01374053955078125
▁Tri 0.767578125
als 0.505859375
▁and 0.88427734375
▁Opt 8.6328125
im 0.43798828125
izing 0.791015625
▁E 4.140625
ffic 0.01334381103515625
acy 0.10137939453125
: 0.26904296875
<0x0A> 0.00572967529296875
Wh 4.71875
ile 0.003387451171875
▁Mar 1.744140625
im 0.00012612342834472656
ast 0.0008983612060546875
at 0.00016701221466064453
▁has 0.64306640625
▁shown 1.3916015625
▁promise 1.8505859375
▁in 0.1212158203125
▁pre 1.908203125
cl 0.27001953125
in 1.4066696166992188e-05
ical 0.00018346309661865234
▁and 2.517578125
▁early 0.74072265625
▁clin 0.353515625
ical 0.00022995471954345703
▁tri 0.7236328125
als 1.8715858459472656e-05
, 0.01479339599609375
▁its 2.60546875
▁true 5.33203125
▁effect 2.224609375
iveness 0.04425048828125
▁remains 1.3193359375
▁to 2.21875
▁be 0.0001741647720336914
▁seen 0.71337890625
. 0.61474609375
▁Ad 7.8359375
van 0.6796875
cing 0.728515625
▁to 3.0625
▁late 4.140625
- 0.040008544921875
stage 0.056121826171875
▁clin 0.4736328125
ical 5.519390106201172e-05
▁tri 0.12457275390625
als 7.152557373046875e-07
▁will 1.2080078125
▁provide 4.140625
▁cru 2.52734375
cial 9.34600830078125e-05
▁ins 1.5439453125
ights 1.52587890625e-05
▁and 3.36328125
▁a 4.546875
▁clearer 2.181640625
▁understanding 0.77880859375
▁of 0.004276275634765625
▁the 1.0478515625
▁drug 0.255615234375
' 0.004146575927734375
s 6.282329559326172e-05
▁overall 5.83203125
▁effic 0.483642578125
acy 3.0994415283203125e-06
▁and 0.79833984375
▁potential 2.49609375
▁side 1.611328125
▁effects 0.004451751708984375
. 0.236083984375
▁British 1.3759765625
▁Bi 0.0007786750793457031
ote 3.9458274841308594e-05
ch 0.0009737014770507812
▁Pl 0.01059722900390625
c 3.0994415283203125e-05
▁must 0.58837890625
▁ensure 2.173828125
▁these 4.875
▁tri 0.34033203125
als 1.7881393432617188e-06
▁are 0.1580810546875
▁conducted 0.61767578125
▁met 7.921875
icul 6.651878356933594e-05
ously 5.602836608886719e-05
▁to 1.81640625
▁maxim 1.94921875
ize 0.00067901611328125
▁Mar 3.216796875
im 0.0001709461212158203
ast 0.0019025802612304688
at 0.0008492469787597656
' 0.00582122802734375
s 0.0005464553833007812
▁th 3.8515625
era 5.602836608886719e-06
pe 1.2755393981933594e-05
ut 6.4373016357421875e-06
ic 0.00033020973205566406
▁benefits 2.6640625
▁and 0.7919921875
▁minim 0.431396484375
ize 0.0006785392761230469
▁any 1.220703125
▁ris 2.357421875
ks 0.0006189346313476562
. 0.763671875
<0x0A> 0.287109375
Con 5.20703125
clusion 0.320068359375
: 0.1915283203125
<0x0A> 2.416015625
As 3.01953125
▁British 0.99609375
▁Bi 0.00244903564453125
ote 5.447864532470703e-05
ch 0.0018787384033203125
▁Pl 0.01241302490234375
c 5.900859832763672e-05
' 1.73046875
s 0.00020778179168701172
▁cancer 3.7421875
▁drug 0.54296875
▁Mar 1.2275390625
im 6.699562072753906e-05
ast 0.0005278587341308594
at 6.413459777832031e-05
▁progress 3.373046875
es 0.0014972686767578125
▁in 3.14453125
▁its 1.9091796875
▁development 2.072265625
, 0.62158203125
▁the 1.3310546875
▁path 3.974609375
▁towards 3.91015625
▁block 1.1494140625
b 8.738040924072266e-05
uster 0.00533294677734375
▁status 0.311767578125
▁faces 5.06640625
▁significant 0.9638671875
▁hur 2.1953125
d 1.430511474609375e-05
les 0.000102996826171875
. 0.402099609375
▁N 6.375
avig 0.2333984375
ating 0.0017147064208984375
▁the 1.365234375
▁complex 0.9140625
▁web 9.453125
▁of 0.01148223876953125
▁regul 0.623046875
atory 0.003719329833984375
▁requirements 1.041015625
, 0.44482421875
▁compet 1.939453125
ing 1.365234375
▁against 6.94921875
▁established 0.33056640625
▁players 0.63671875
, 0.250244140625
▁se 4.05078125
cur 0.00010442733764648438
ing 1.4781951904296875e-05
▁ade 2.74609375
qu 1.430511474609375e-05
ate 4.1365623474121094e-05
▁fund 0.250244140625
ing 0.00011157989501953125
, 0.09222412109375
▁and 0.2841796875
▁optim 1.451171875
izing 0.0005254745483398438
▁clin 4.01171875
ical 0.0005536079406738281
▁trial 1.53515625
▁out 1.529296875
comes 5.257129669189453e-05
▁are 1.6796875
▁just 1.7138671875
▁some 1.376953125
▁of 0.009490966796875
▁the 0.01534271240234375
▁challeng 0.393310546875
es 0.001422882080078125
▁to 4.26171875
▁overcome 1.5751953125
. 0.6376953125
▁Nevertheless 3.0
, 0.000240325927734375
▁the 0.8583984375
▁immense 6.80078125
▁potential 0.2459716796875
▁and 2.431640625
▁early 2.896484375
▁promise 2.064453125
▁exhib 5.94921875
ited 0.0009613037109375
▁by 0.020599365234375
▁Mar 0.1822509765625
im 8.320808410644531e-05
ast 0.000762939453125
at 8.90493392944336e-05
▁offer 3.3984375
▁hope 1.16015625
▁to 4.28125
▁patients 1.447265625
▁and 0.83447265625
▁the 1.7060546875
▁wider 4.37890625
▁medical 2.53125
▁community 0.07452392578125
. 1.046875
▁The 2.712890625
▁bi 1.8095703125
ote 0.005031585693359375
ch 0.0192413330078125
▁industry 0.0728759765625
▁eager 1.365234375
ly 5.53131103515625e-05
▁a 0.0220947265625
wa 1.1920928955078125e-07
its 1.3947486877441406e-05
▁the 2.25
▁next 1.8681640625
▁steps 1.2607421875
, 2.6484375
▁as 2.384765625
▁successful 6.1796875
▁navigation 11.125
▁through 2.544921875
▁these 0.76123046875
▁hur 2.154296875
d 9.775161743164062e-06
les 0.00020992755889892578
▁could 1.5654296875
▁potentially 3.677734375
▁make 4.1328125
▁Mar 0.70947265625
im 0.00011944770812988281
ast 0.000560760498046875
at 0.0001068115234375
▁a 0.54248046875
▁game 2.169921875
- 0.1458740234375
ch 0.000865936279296875
anger 0.5107421875
▁in 0.775390625
▁cancer 0.58349609375
▁treatment 0.0626220703125
. 0.0770263671875
